GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IntelliPharmaCeutics International Inc (OTCPK:IPCIF) » Definitions » Owner Earnings per Share (TTM)

IntelliPharmaCeutics International (IntelliPharmaCeutics International) Owner Earnings per Share (TTM) : -0.01 (As of Aug. 2023)


View and export this data going back to 1996. Start your Free Trial

What is IntelliPharmaCeutics International Owner Earnings per Share (TTM)?

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

IntelliPharmaCeutics International's Owner Earnings per Share (TTM) ended in Aug. 2023 was $-0.01. It's Price-to-Owner-Earnings ratio for today is 0.


The historical rank and industry rank for IntelliPharmaCeutics International's Owner Earnings per Share (TTM) or its related term are showing as below:



IPCIF's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 31.62
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

IntelliPharmaCeutics International's Earnings per Share (Diluted) for the three months ended in Aug. 2023 was $-0.06. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Aug. 2023 was $-0.09. It's PE Ratio ratio for today is At Loss.

IntelliPharmaCeutics International's EPS without NRI for the three months ended in Aug. 2023 was $-0.06. Its EPS without NRI for the trailing twelve months (TTM) ended in Aug. 2023 was $-0.09. It's PE Ratio without NRI ratio for today is At Loss.


IntelliPharmaCeutics International Owner Earnings per Share (TTM) Historical Data

The historical data trend for IntelliPharmaCeutics International's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IntelliPharmaCeutics International Owner Earnings per Share (TTM) Chart

IntelliPharmaCeutics International Annual Data
Trend Nov13 Nov14 Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.93 -0.33 -0.07 -0.12 -0.03

IntelliPharmaCeutics International Quarterly Data
Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.05 -0.03 -0.02 -0.03 -0.01

Competitive Comparison of IntelliPharmaCeutics International's Owner Earnings per Share (TTM)

For the Biotechnology subindustry, IntelliPharmaCeutics International's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IntelliPharmaCeutics International's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IntelliPharmaCeutics International's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where IntelliPharmaCeutics International's Price-to-Owner-Earnings falls into.



IntelliPharmaCeutics International Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

IntelliPharmaCeutics International's Owner Earnings per Share (TTM) Calculation:

TTM / Last Quarter Average of Last 20 Quarters
Net Income -3.17
Depreciation, Depletion and Amortization 0.18
Change In Deferred Tax 0.00
5Y Average of Maintenance Capital Expenditure 0.01
Change In Working Capital 2.66
Shares Outstanding (Diluted Average) 33.09

1. Start with "Net Income" from income statement. IntelliPharmaCeutics International's Net Income for the trailing twelve months (TTM) ended in Aug. 2023 was $-3.17 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. IntelliPharmaCeutics International's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Aug. 2023 was $0.18 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. IntelliPharmaCeutics International's Change In Deferred Tax for the trailing twelve months (TTM) ended in Aug. 2023 was $0.00 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = $0.01 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous quarter. If the revenue decreased from the previous quarter, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous quarter, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

IntelliPharmaCeutics International's 5-Year Average Maintenance Capital Expenditure = $0.01 Mil

5. "Change In Working Capital" is from cashflow statement. IntelliPharmaCeutics International's Change In Working Capital for the trailing twelve months (TTM) ended in Aug. 2023 was $2.66 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. IntelliPharmaCeutics International's Shares Outstanding (Diluted Average) for the months ended in Aug. 2023 was 33.093 Mil.

IntelliPharmaCeutics International's Onwer Earnings Per Share for Aug. 2023 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( -3.174 +0.175+0
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-0.0128+2.657)/33.093
=-0.01

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=0.06/-0.01
=0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


IntelliPharmaCeutics International Owner Earnings per Share (TTM) Related Terms

Thank you for viewing the detailed overview of IntelliPharmaCeutics International's Owner Earnings per Share (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


IntelliPharmaCeutics International (IntelliPharmaCeutics International) Business Description

Traded in Other Exchanges
Address
30 Worcester Road, Toronto, ON, CAN, M9W 5X2
IntelliPharmaCeutics International Inc is a pharmaceutical company. The company is engaged in the research, development, and manufacturing of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of a range of existing and new pharmaceuticals. Its ongoing drug development programs are at various stages of development in therapeutic areas that include neurology, cardiovascular, GIT, and pain. The company's product, a generic of Focalin XR, is partnered with Par Pharmaceutical, Inc. and received FDA approval. It derives revenue from the United States.

IntelliPharmaCeutics International (IntelliPharmaCeutics International) Headlines

From GuruFocus

Intellipharmaceutics Announces Fiscal Year 2020 Results

By ACCESSWIRE ACCESSWIRE 03-01-2021